Original Literature | Model OverView |
---|---|
Publication
Title
RAPping production of type I interferon in pDCs through mTOR.
Affiliation
Department of Biochemistry and the McGill Cancer Centre, McGill University,Montreal, Quebec, Canada.
Abstract
The production of type I interferon -- the first line of defense against virusinfection and critical for innate immunity -- in plasmacytoid dendritic cellsrelies on the mammalian target of rapamycin.
PMID
18800159
|
Entity
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
p70S6K2
--
MO000017539
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2332
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000017539 |
--
p70S6K1
--
MO000017540
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2333
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000017540 |
--
eIF-4E
--
MO000020752
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m5183
10
infinite
0
TRANSPATH | MO000020752 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
p70S6K2{p}
--
e11
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m11
0
infinite
0
--
4E-BP{p}
--
e12
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m12
0
infinite
0
--
4E-BP:eIF-4E
--
e13
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m13
0
infinite
0
--
EIF4B{p}
--
e14
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m14
0
infinite
0
--
CpGA
--
e15
cso30:c:Dna
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m15
0
infinite
0
--
mTOR{p}
--
e16
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m16
0
infinite
0
--
rapamycin
--
e17
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
csml-variable:Double
m17
0
infinite
0
--
rapamycin:FKBP12
--
e18
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m18
0
infinite
0
--
mTORC1:rapamycin:FKBP12
--
e19
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
--
e20
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeLumen
--
--
--
csml-variable:Double
m20
0
infinite
0
--
--
e21
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Endosome
--
--
--
csml-variable:Double
m21
0
infinite
0
--
--
e22
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeMembrane
--
--
--
csml-variable:Double
m22
0
infinite
0
--
CpG-A:TLR9
--
e23
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m23
0
infinite
0
--
TLR7 ligand:TLR7
--
e24
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m24
0
infinite
0
--
type I interferon
--
e25
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m25
0
infinite
0
--
type I interferon
--
e26
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m26
0
infinite
0
--
CpG-A:TLR9:MYD88
--
e27
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m27
0
infinite
0
--
CpG-A:TLR9:MYD88:TRAF6:IRAK1:IRAk4:IRF-7:Btk
--
e28
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m28
0
infinite
0
--
CpG-A:TLR9:MYD88:TRAF6:IRAK1:IRAk4:Btk
--
e29
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
type I interferon
--
e31
cso30:c:Dna
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m31
0
infinite
0
--
IFN-alpha4
--
e32
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m32
0
infinite
0
--
IFN-beta1
--
e33
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m33
0
infinite
0
--
IFI44
--
e34
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m34
0
infinite
0
--
IFI202B
--
e35
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m35
0
infinite
0
--
CCL7
--
e36
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m36
0
infinite
0
--
CCL8
--
e37
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m37
0
infinite
0
--
CCL12
--
e38
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m38
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
raptor:mTOR:mLST8
--
e5
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
p70S6K1{p}
--
e6
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
p1
p1
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
stoichiometry:c117 : 1
stoichiometry:c4 : 1
m2018*m16445*m11333*0.1
nodelay
--
0
PMID: 18800159 mTOR associates with the adaptor proteins raptor and LST8 (G¦ÂL) to form a complex called ¡ÆmTORC1¡Ç that initiates translation by phosphorylating members of at least two families of translational modulators, the p70 ribosomal S6 kinases (S6Ks)1 and 2 (S6K1,2) and the eIF4E-binding proteins (4E-BPs). PMID: 18800159 In the second mechanism, rapamycin treatment disrupts mTOR-raptor interaction, which prevents mTOR from phosphorylating 4E-BPs.
p10
p10
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c29 : 1
stoichiometry:c28 : 1
stoichiometry:c27 : 1
stoichiometry:c115 : 1
m23*m13*0.1
nodelay
--
0
PMID: 18800159 the TLR9 ligand CpG-A triggers rapid phosphorylation of mTOR and its ¡Ædownstream¡Ç targets 4E-BPs and S6Ks.
p11
p11
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c30 : 1
stoichiometry:c32 : 1
stoichiometry:c31 : 1
m2332*m23*0.1
nodelay
--
0
PMID: 18800159 the TLR9 ligand CpG-A triggers rapid phosphorylation of mTOR and its ¡Ædownstream¡Ç targets 4E-BPs and S6Ks.
p12
p12
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c33 : 1
stoichiometry:c35 : 1
stoichiometry:c34 : 1
m2333*m23*0.1
nodelay
--
0
PMID: 18800159 the TLR9 ligand CpG-A triggers rapid phosphorylation of mTOR and its ¡Ædownstream¡Ç targets 4E-BPs and S6Ks.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c36 : 1
stoichiometry:c44 : 1
stoichiometry:c37 : 1
m17*m2224*0.1
nodelay
--
0
PMID: 18800159 Pulendran and colleagues now show that phosphorylation of mTOR, 4E-BPs and S6Ks in response to TLR9 activation is blocked by the highly specific drug rapamycin, a macrolide that, in a complex with the immunophilin FKBP12, binds to mTORC1 and inhibits mTORC1 activity
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c38 : 1
stoichiometry:c39 : 1
stoichiometry:c40 : 1
m18*m5*0.1
nodelay
--
0
PMID: 18800159 Pulendran and colleagues now show that phosphorylation of mTOR, 4E-BPs and S6Ks in response to TLR9 activation is blocked by the highly specific drug rapamycin, a macrolide that, in a complex with the immunophilin FKBP12, binds to mTORC1 and inhibits mTORC1 activity
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c45 : 1
stoichiometry:c47 : 1
stoichiometry:c46 : 1
m19828*m15*0.1
nodelay
--
0
PMID: 18800159 both TLR7- and TLR9-mediated production of type I interferon, tumor necrosis factor and interleukin 6 (IL-6) is suppressed in human and mouse pDCs treated with rapamycin.
p16
p16
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c48 : 1
stoichiometry:c49 : 1
stoichiometry:c51 : 1
stoichiometry:c50 : 1
m23*m93309*0.1
nodelay
--
0
PMID: 18800159 both TLR7- and TLR9-mediated production of type I interferon, tumor necrosis factor and interleukin 6 (IL-6) is suppressed in human and mouse pDCs treated with rapamycin.
p17
p17
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c53 : 1
stoichiometry:c54 : 1
stoichiometry:c55 : 1
stoichiometry:c52 : 1
m93309*m24*0.1
nodelay
--
0
PMID: 18800159 both TLR7- and TLR9-mediated production of type I interferon, tumor necrosis factor and interleukin 6 (IL-6) is suppressed in human and mouse pDCs treated with rapamycin.
p18
p18
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c60 : 1
stoichiometry:c62 : 1
stoichiometry:c57 : 1
m93248*m23*0.1
nodelay
--
0
PMID: 18800159 both TLR7- and TLR9-mediated production of type I interferon, tumor necrosis factor and interleukin 6 (IL-6) is suppressed in human and mouse pDCs treated with rapamycin.
p19
p19
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c58 : 1
stoichiometry:c61 : 1
stoichiometry:c63 : 1
stoichiometry:c59 : 1
m93248*m24*0.1
nodelay
--
0
PMID: 18800159 both TLR7- and TLR9-mediated production of type I interferon, tumor necrosis factor and interleukin 6 (IL-6) is suppressed in human and mouse pDCs treated with rapamycin.
p2
p2
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c5 : 1
stoichiometry:c6 : 1
stoichiometry:c41 : 1
stoichiometry:c7 : 1
m5*m2333*0.1
nodelay
--
0
PMID: 18800159 mTOR associates with the adaptor proteins raptor and LST8 (G¦ÂL) to form a complex called ¡ÆmTORC1¡Ç that initiates translation by phosphorylating members of at least two families of translational modulators, the p70 ribosomal S6 kinases (S6Ks)1 and 2 (S6K1,2) and the eIF4E-binding proteins (4E-BPs). PMID: 18800159 Pulendran and colleagues now show that phosphorylation of mTOR, 4E-BPs and S6Ks in response to TLR9 activation is blocked by the highly specific drug rapamycin, a macrolide that, in a complex with the immunophilin FKBP12, binds to mTORC1 and inhibits mTORC1 activity
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c66 : 1
stoichiometry:c69 : 1
stoichiometry:c70 : 1
stoichiometry:c64 : 1
m25*m23*0.1
nodelay
--
0
PMID: 18800159 both TLR7- and TLR9-mediated production of type I interferon, tumor necrosis factor and interleukin 6 (IL-6) is suppressed in human and mouse pDCs treated with rapamycin.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c67 : 1
stoichiometry:c68 : 1
stoichiometry:c71 : 1
stoichiometry:c65 : 1
m25*m24*0.1
nodelay
--
0
PMID: 18800159 both TLR7- and TLR9-mediated production of type I interferon, tumor necrosis factor and interleukin 6 (IL-6) is suppressed in human and mouse pDCs treated with rapamycin.
p22
p22
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c74 : 1
stoichiometry:c72 : 1
m94230*0.1
nodelay
--
0
PMID: 18800159 The effect of rapamycin is not limited to pDCs, as the production of IL-10, IL-6 and tumor necrosis factor is also impaired in bone marrow? derived DCs treated with rapamycin
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c75 : 1
stoichiometry:c78 : 1
stoichiometry:c79 : 1
stoichiometry:c76 : 1
m23*m1572*m6*0.1
nodelay
--
0
PMID: 18800159 they find that a decrease in S6K activity resulting from the use of rapamycin or siRNA specific for S6K1,2 impedes the production of type I interferon and formation of the TLR9-MyD88 complex. PMID: 18800159 S6K phosphorylation mediated by mTOR promotes formation of the TLR9-MyD88 complex
p24
p24
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c77 : 1
stoichiometry:c80 : 1
stoichiometry:c81 : 1
stoichiometry:c82 : 1
stoichiometry:c83 : 1
stoichiometry:c84 : 1
stoichiometry:c85 : 1
m27*m183*m17258*m184*m367*m980*0.1
nodelay
--
0
PMID: 18800159 The interaction of TLR with MyD88 in pDCs elicits the formation of multifactor signaling transduction complex that contains the kinases IRAK1 and IRAK4, the ubiquitin ligase TRAF6, the tyrosine kinase BTK and IRF7
p25
p25
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c86 : 1
stoichiometry:c87 : 1
stoichiometry:c88 : 1
m28*0.1
nodelay
--
0
PMID: 18800159, 18641647 IRF7 is phosphorylated by IRAK1- IRAK4 and then translocates to the nucleus, where it initiates the transcription of genes encoding type I interferons
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c89 : 1
stoichiometry:c90 : 1
m19325*0.1
nodelay
--
0
PMID: 18800159, 18641647 IRF7 is phosphorylated by IRAK1- IRAK4 and then translocates to the nucleus, where it initiates the transcription of genes encoding type I interferons
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c92 : 1
stoichiometry:c93 : 1
stoichiometry:c91 : 1
m30*m31*0.1
nodelay
--
0
PMID: 18800159, 18641647 IRF7 is phosphorylated by IRAK1- IRAK4 and then translocates to the nucleus, where it initiates the transcription of genes encoding type I interferons
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c110 : 1
stoichiometry:c96 : 1
m23*0.1
nodelay
--
0
PMID: 18800159 the expression of a subset of genes encoding interferons and cytokines such as interferon-¦Á4, interferon-¦Â1, IFI44, IFI202B, CCL7, CCL8 and CCL12 is induced by CpG-A but is repressed by rapamycin.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c104 : 1
stoichiometry:c112 : 1
stoichiometry:c100 : 1
m23*0.1
nodelay
--
0
PMID: 18800159 the expression of a subset of genes encoding interferons and cytokines such as interferon-¦Á4, interferon-¦Â1, IFI44, IFI202B, CCL7, CCL8 and CCL12 is induced by CpG-A but is repressed by rapamycin.
p3
p3
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c8 : 1
stoichiometry:c10 : 1
stoichiometry:c42 : 1
stoichiometry:c9 : 1
m2332*m5*0.1
nodelay
--
0
PMID: 18800159 mTOR associates with the adaptor proteins raptor and LST8 (G¦ÂL) to form a complex called ¡ÆmTORC1¡Ç that initiates translation by phosphorylating members of at least two families of translational modulators, the p70 ribosomal S6 kinases (S6Ks)1 and 2 (S6K1,2) and the eIF4E-binding proteins (4E-BPs). PMID: 18800159 Pulendran and colleagues now show that phosphorylation of mTOR, 4E-BPs and S6Ks in response to TLR9 activation is blocked by the highly specific drug rapamycin, a macrolide that, in a complex with the immunophilin FKBP12, binds to mTORC1 and inhibits mTORC1 activity
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c107 : 1
stoichiometry:c113 : 1
stoichiometry:c99 : 1
m23*0.1
nodelay
--
0
PMID: 18800159 the expression of a subset of genes encoding interferons and cytokines such as interferon-¦Á4, interferon-¦Â1, IFI44, IFI202B, CCL7, CCL8 and CCL12 is induced by CpG-A but is repressed by rapamycin.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c101 : 1
stoichiometry:c109 : 1
stoichiometry:c94 : 1
m23*0.1
nodelay
--
0
PMID: 18800159 the expression of a subset of genes encoding interferons and cytokines such as interferon-¦Á4, interferon-¦Â1, IFI44, IFI202B, CCL7, CCL8 and CCL12 is induced by CpG-A but is repressed by rapamycin.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c105 : 1
stoichiometry:c111 : 1
stoichiometry:c95 : 1
m23*0.1
nodelay
--
0
PMID: 18800159 the expression of a subset of genes encoding interferons and cytokines such as interferon-¦Á4, interferon-¦Â1, IFI44, IFI202B, CCL7, CCL8 and CCL12 is induced by CpG-A but is repressed by rapamycin.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c102 : 1
stoichiometry:c108 : 1
stoichiometry:c97 : 1
m23*0.1
nodelay
--
0
PMID: 18800159 the expression of a subset of genes encoding interferons and cytokines such as interferon-¦Á4, interferon-¦Â1, IFI44, IFI202B, CCL7, CCL8 and CCL12 is induced by CpG-A but is repressed by rapamycin.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c106 : 1
stoichiometry:c114 : 1
stoichiometry:c98 : 1
m23*0.1
nodelay
--
0
PMID: 18800159 the expression of a subset of genes encoding interferons and cytokines such as interferon-¦Á4, interferon-¦Â1, IFI44, IFI202B, CCL7, CCL8 and CCL12 is induced by CpG-A but is repressed by rapamycin.
p35
p35
cso30:i:ME_Translation
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c118 : 1
stoichiometry:c120 : 1
stoichiometry:c121 : 1
stoichiometry:c119 : 1
m93631*m5183*0.1
nodelay
--
0
PMID: 18800159 The mTOR-dependent phophorylation of 4 E-BPs results in low-affinity binding to eIF4E and thus elicit more translation of IRF7 mRNA. PMID: 18800159, 18272964 One of these mRNAs, IRF7, has been shown to be translationally controlled by 4E-BPs and is responsible for the enhanced production of type I interferon and virus-resistant phenotype of MEFs doubly deficient in 4E-BP1 and 4E-BP2. PMID: 18800159 hypophosphorylated 4E-BPs then bind to the cap-binding protein eIF4E with high affinity, thus decreasing the translation of a subset of mRNAs.
p4
p4
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c11 : 1
stoichiometry:c43 : 1
stoichiometry:c13 : 1
stoichiometry:c12 : 1
stoichiometry:c116 : 1
m5*m13*0.1
nodelay
--
0
PMID: 18800159 mTOR associates with the adaptor proteins raptor and LST8 (G¦ÂL) to form a complex called ¡ÆmTORC1¡Ç that initiates translation by phosphorylating members of at least two families of translational modulators, the p70 ribosomal S6 kinases (S6Ks)1 and 2 (S6K1,2) and the eIF4E-binding proteins (4E-BPs). PMID: 18800159 Pulendran and colleagues now show that phosphorylation of mTOR, 4E-BPs and S6Ks in response to TLR9 activation is blocked by the highly specific drug rapamycin, a macrolide that, in a complex with the immunophilin FKBP12, binds to mTORC1 and inhibits mTORC1 activity
p5
p5
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c14 : 1
stoichiometry:c15 : 1
m5183*m2314*0.1
nodelay
--
0
PMID: 18800159 4E-BPs (of which three forms exist in mammals) inhibit translation by binding the cap-binding protein eIF4E
PMID: 18800159 4E-BPs (of which three forms exist in mammals) inhibit translation by binding the cap-binding protein eIF4E
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c18 : 1
stoichiometry:c20 : 1
stoichiometry:c19 : 1
m38945*m11*0.1
nodelay
--
0
PMID: 18800159 the S6Ks phosphorylate and activate (among other substrates) eIF4B, a translation-initiation factor.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c21 : 1
stoichiometry:c23 : 1
stoichiometry:c22 : 1
m38945*m6*0.1
nodelay
--
0
PMID: 18800159 the S6Ks phosphorylate and activate (among other substrates) eIF4B, a translation-initiation factor.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c24 : 1
stoichiometry:c26 : 1
stoichiometry:c25 : 1
m2018*m23*0.1
nodelay
--
0
PMID: 18800159 the TLR9 ligand CpG-A triggers rapid phosphorylation of mTOR and its ¡Ædownstream¡Ç targets 4E-BPs and S6Ks.
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--